Literature DB >> 6979236

Prognosis of asymptomatic or mildly symptomatic patients with coronary artery disease.

K M Kent, D R Rosing, C J Ewels, L Lipson, R Bonow, S E Epstein.   

Abstract

One hundred forty-seven asymptomatic or mildly symptomatic patients with coronary artery disease, who did not have significant left main coronary occlusion and had an ejection fraction greater than 20 percent, were followed up prospectively for 6 to 67 months (average 25). Significant obstruction of one coronary artery was present in 28 percent of patients, of two coronary arteries in 31 percent and of three coronary arteries in 41 percent. Ejection fraction was 55 percent or greater in 69 percent of patients. During the follow-up there were eight deaths (annual mortality rate 3 percent for the entire group, 1.5 percent for patients with single and double vessel disease but 6 percent for those with triple vessel disease). Better definition of high and low risk subgroups of patients with three vessel disease was accomplished with exercise testing. Despite a history of mild symptoms, 25 percent of the patients with triple vessel disease exhibited poor exercise capacity on exercise testing after administration of beta adrenoceptor blocking agents and nitrates was discontinued; of these, 40 percent either died (20 percent) or had progressive symptoms requiring operation (20 percent) (annual mortality rate 9 percent). Of the patients with good exercise capacity, only 22 percent either died (7 percent) or had progressive symptoms (15 percent) (annual mortality rate 4 percent). Thus, prognosis is excellent in patients with no or mild symptoms who have one or two vessel coronary disease. Patients with three vessel disease who have good exercise capacity documented by objective testing have an annual mortality rate of 4 percent. However, because patients with three vessel disease and poor exercise capacity have an extremely grave prognosis, it would appear reasonable to recommend coronary bypass surgery for this subgroup, even in the absence of supporting data derived from a definitive randomized study.

Entities:  

Mesh:

Year:  1982        PMID: 6979236     DOI: 10.1016/0002-9149(82)90198-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Early Risk Stratification with Dipyridamole Stress Echo in a Patient with Intermediate Lesion in the Right Coronary Artery, 24 Hours after Percutaneous Coronary Intervention.

Authors:  S Carmargo; R D Rampersad
Journal:  West Indian Med J       Date:  2015-02-10       Impact factor: 0.171

2.  Cost-effective investigation of patients with suspected transient ischaemic attacks.

Authors:  G J Hankey; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 3.  Coronary bypasses.

Authors:  M C Petch
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-20

4.  Whole-body MR vascular screening detects unsuspected concomitant vascular disease in coronary heart disease patients.

Authors:  Susanne C Ladd; Joerg F Debatin; Andreas Stang; Katja Bromen; Susanne Moebus; Michael Nuefer; Elke Gizewski; Isabel Wanke; Arnd Doerfler; Mark E Ladd; Jens Benemann; Raimund Erbel; Michael Forsting; Axel Schmermund; Karl-Heinz Jöckel
Journal:  Eur Radiol       Date:  2006-10-07       Impact factor: 5.315

5.  Risk stratification of patients with coronary artery disease and left ventricular dysfunction by exercise radionuclide angiography and exercise electrocardiography.

Authors:  G Mazzotta; L Pace; R O Bonow
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

Review 6.  Silent ischemia: a relevant problem in patients with coronary artery disease?

Authors:  W Rutishauser; A Righetti; P Roy
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

Review 7.  The combination of antianginal drugs: effects and indications.

Authors:  P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.